Rothschild Redburn initiates Solventum stock with Sell rating

Rothschild Redburn initiated coverage of Solventum (NYSE:SOLV) with a Sell and $60 price target, implying ~10% downside from the $65.69 share price. Solventum reported Q4 2025 EPS $1.57 vs $1.75 forecast and revenue $2.0B (+3.5% organic), while company targets 4-5% organic growth by FY2028 versus ~1% in FY2024 and 0.86% LTM revenue growth. Rothschild cites execution risk, spin-related expenses and exposure to commoditized medical segments; several firms (Piper Sandler, Jefferies, CIBC) nevertheless reiterated positive ratings with price targets of $98, $32 and $37 respectively.

Analysis

The market is underpricing execution drag from a multi-division carve‑out: rebranding, stand‑up of shared services and idiosyncratic end‑market exposure all elongate the path from revenue stability to sustainable margin expansion. That dynamic transfers stress to upstream suppliers and channel partners (inventory financing, receivables) and creates a two‑tier competitive field where scale players with recurring consumable or software lock‑in capture pricing power while mid‑tier incumbents compete on price. Over the next 6–18 months expect the primary volatility drivers to be quarter‑by‑quarter guidance deltas and one‑off separation costs; absent clear evidence of operating leverage re‑emerging, multiples should remain under pressure.

Second‑order winners include suppliers and service vendors who can reprice or reallocate capacity away from a pressured OEM — they’ll see shorter, higher‑margin contracts as the carved‑out firm trims SKU breadth. Conversely, competitors that sell differentiated software or proprietary consumables will take share if the carved entity doubles down on commoditized offerings; look for margin divergence of 300–600bps across peers within 12 months. Regulatory or macro tailwinds (dental/narrow elective recovery) could provide a cyclical lift, but that is distinct from the structural work required to hit mid‑cycle targets.

Key tail risks: a successful, accretive tuck‑in or activist‑led simplification could erase much downside within 9–15 months, while an execution miss or prolonged brand re‑launch could force deeper price cuts and multiple compression. Near term catalysts to monitor are sequential op‑leverage improvements, clear Synergy 1.0 milestones, and supplier renegotiations; any of these materially change the risk/reward and should prompt active position re‑sizing.

Key Decisions for Investors

• Short SOLV stock (or synthetic short via OTM put calendar) over 6–12 months — target 20–30% downside if no clear op‑leverage signal within two quarters; hard stop at +15% to limit event risk (activist/M&A).
• Pair trade: short SOLV / long MDT (or DHR) 1:1 over 3–12 months to isolate idiosyncratic execution risk — expect spread widening of 300–600bps in margin multiple; use equal notional and rebalance monthly.
• Buy a cost‑limited put spread on SOLV (6–12 month expiries, 20%/35% strikes) to hedge downside from guidance misses while capping premium outlay — aim for 3:1 payoff vs premium if realized.
• Long MMM (3M) selective exposure over 9–18 months as a supplier/rebalancing beneficiary: small size (3–5% portfolio), skewed upside if contracts reprice or if working capital normalizes; trim on +25% move or on confirmation of improved order flows.